MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival at 12 months for patients with blood cancer receiving allogenic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors, as well as MaaT034 that optimize immune checkpoint inhibitor treatment. MaaT Pharma SA was incorporated in 2014 and is headquartered in Lyon, France.
Frequently asked questions
What sector does Maat Pharma SA (MAAT) operate in?
Maat Pharma SA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Maat Pharma SA (MAAT) current stock price?
As of the latest data, Maat Pharma SA stock price is €2.94, with a previous close of €2.95. Maat Pharma SA lost -€0.01 in the last trading session, representing a -0.34% loss.
What is Maat Pharma SA (MAAT) current market capitalization?
Maat Pharma SA market cap is approximately 55.32 million.
What is Maat Pharma SA (MAAT) Earnings Per Share (EPS)?
The trailing EPS is -€1.90, and the forward EPS is -€1.11.
Does Maat Pharma SA (MAAT) pay dividends?
No. Maat Pharma SA does not pay a dividend.
What is Maat Pharma SA (MAAT) beta (volatility) score?
Maat Pharma SA has a beta of 0.403, indicating lower volatility than the overall market.
